Morcos, Peter N.

Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer

Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., Ou, S.-H. I., Pérol, M., Dziadziuszko, R., Rosell, R., et al. (2017) · New England Journal of Medicine

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 2,527

Physiologically Based Absorption Modeling to Explore the Impact of Food and Gastric pH Changes on the Pharmacokinetics of Alectinib

Parrott, N. J., Yu, L. J., Takano, R., Nakamura, M., & Morcos, P. N. (2016) · The AAPS Journal

Drug Solubulity and Delivery SystemsPharmaceutical studies and practices

Cited by 77

Pharmacokinetics and pharmacodynamics of single subcutaneous doses of tocilizumab administered with or without rHuPH20

Morcos, P. N., Zhang, X., McIntyre, C., Bittner, B., Rowell, L., & Hussain, Z. (2013) · Int. Journal of Clinical Pharmacology and Therapeutics

Rheumatoid Arthritis Research and TherapiesBiosimilars and Bioanalytical Methods

Cited by 23

Population Pharmacokinetics and Exposure-Response Analyses for Glofitamab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Confirmation of Efficacy and CRS Mitigation in Patients with Step-up Dosing

Djebli, N., Morcos, P. N., Jaminion, F., Guerini, E., Kratochwil, N. A., Justies, N., Schick, E., Kwan, A., Humphrey, K., Lundberg, L., et al. (2020) · Blood

Lymphoma Diagnosis and TreatmentMonoclonal and Polyclonal Antibodies Research

Cited by 16